DEA telemedicine prescribing rule remains under White House review
Aug 6, 2026 – Nov 15, 2026
-
DEA controlled-substance telehealth flexibility set to expire December 31, 2026
While the January 2025 rule permanently allowing telehealth buprenorphine prescribing for opioid use disorder stands, DEA's broader Schedule II through V telemedicine prescribing extension, last renewed December 31, 2025, runs out at year-end 2026 with no permanent rule yet published.
Read this issue → -
DEA telemedicine registration rule at OIRA
The DEA's final special registration rule for prescribing controlled substances by telemedicine went to OIRA on August 25, 2026, while the temporary flexibilities expire December 31, 2026 and the January 2025 proposal drew more than 6,400 comments.
Read this issue → -
DEA telemedicine rule still at White House
The DEA's final special registration rule for telemedicine prescribing has been under OIRA review since August 25, with a stakeholder meeting set for today, while current controlled-substance flexibilities run only through December 31, 2026.
Read this issue → -
DEA telemedicine prescribing rule remains under White House review
The DEA's final rule on special registrations for telemedicine prescribing of controlled substances has been at OIRA since August 25 with no text public, while current flexibilities expire December 31, 2026.
Read this issue →